Second-line chemotherapy for non-small cell lung cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  De Marinis, Filippo ^a,b   De Santis, S ^a   De Petris, L ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b FoRO (Oncological Research Foundation)   (Italy)

Author keywords

Docetaxel; NSCLC; Pemetrexed; Second line chemotherapy

Indexed keywords

CORTICOSTEROID; CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; FOLIC ACID; GEFITINIB; IFOSFAMIDE; NAVELBINE; NEW DRUG; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; VITAMIN;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DRUG ACTIVITY; DRUG APPROVAL; DRUG ERUPTION; DRUG INDICATION; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GERIATRIC PATIENT; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPSIS; VITAMIN SUPPLEMENTATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIETARY SUPPLEMENTS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MULTICENTER STUDIES AS TOPIC; SURVIVAL ANALYSIS; TAXOIDS; VITAMINS;

EID: 33745625668     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj954     Document Type: Review

References (19)

1. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18(10): 2095-2103.
2. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18(12): 2354-2362.
3. Camps C, Massuti B, Jimenez AM et al. Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): A Spanish Lung Cancer Group (SLCG) phase III trial. Proc Am Soc Clin Oncol 2003; 22: Abstr 2514.
4. Schuette W, Nagel S, Serke M et al. Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study. J Clin Oncol 2004; 22(14S): Abstr 7036.
5. Gridelli C, Gallo C, Di Maio M et al. A randomised clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004; 91(12): 1996-2004.
6. Gervais R, Ducolone A, Breton JL et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005; 16(1): 90-96.
7. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002; 29(6 Suppl 18): 3-17.
8. Smit EF, Mattson K, von Pawel J et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study. Ann Oncol 2003; 14(3): 455-460.
9. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1(7): 545-552.
10. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22(9): 1589-1597.
11. Bunn P, Rosell R, Fossella F et al. An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer (NSCLC): The impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel. Lung Cancer 2005; 49(Suppl 2): S86.
12. Bhalla S, Thatcher N, Reck M et al. Does reporting expected duration and severity of adverse events provide clinically relevant information when selecting a chemotherapy regimen? An example using pemetrexed and docetaxel. Lung Cancer 2005; 49 (Suppl 2): S86.
13. Kelly K, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2005; 49(Suppl 2): S251.
14. De Marinis F, Pereira JR, Park K et al. Does second-line therapy for non-small cell lung cancer (NSCLC) result in symptom palliation? Analysis of 484 patients from a randomized trial of pemetrexed vs. docetaxel. J Clin Oncol 2004; 22(14S): Abstr 7035.
15. De Marinis F, Crino L, Stynes G et al. Improved toxicity profile of pemetrexed vs. docetaxel in previously treated non-small cell lung cancer patients translates to cost savings in Italy. Ann Oncol 2004; 15(Suppl 3): Abstr 719P.
16. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21(12): 2237-2246.
17. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. Jama 2003; 290(16): 2149-2158.
18. Thatcher N, Chang A, Parikh P et al. ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 2005; 49(Suppl 2): S4.
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132.